TC BioPharm Approves Special ADS Dividend

Ticker: TCBWF · Form: 6-K · Filed: Dec 31, 2024 · CIK: 1872812

Sentiment: bullish

Topics: dividend, shareholder-return

TL;DR

TC BioPharm is giving shareholders 0.25 ADSs for every 1 ADS they own, announced Dec 18.

AI Summary

TC BioPharm (Holdings) plc announced on December 18, 2024, that its Board of Directors has approved a special dividend. Shareholders will receive 0.25 American Depositary Shares (ADSs) for every 1 ADS they hold.

Why It Matters

This special dividend distribution of ADSs could be seen as a positive signal from the company's management, potentially increasing shareholder value.

Risk Assessment

Risk Level: low — The filing is a routine announcement of a dividend distribution and does not contain significant financial or operational risks.

Key Numbers

Key Players & Entities

FAQ

What is the record date for the special dividend?

The filing does not specify a record date for the special dividend.

When will the special dividend be paid out?

The filing does not provide a specific payment date for the special dividend.

What is the total number of ADSs expected to be distributed?

The filing does not state the total number of ADSs to be distributed, as it depends on the total number of ADSs outstanding.

Are there any conditions attached to receiving the special dividend?

The filing states the Board of Directors has approved the dividend, but does not mention any specific conditions for shareholders to receive it.

What is the tax implication of this special dividend for shareholders?

The filing does not provide information on the tax implications of the special dividend.

Filing Stats: 345 words · 1 min read · ~1 pages · Grade level 19 · Accepted 2024-12-31 14:10:48

Filing Documents

From the Filing

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Translation of registrant’s name into English) Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kingdom +44 (0) 141 433 7557 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On December 18, 2024, TC Biopharm (Holdings) PLC (the “Company”) publicly a nnounced that its Board of Directors has approved a special dividend to its shareholders of 0.25 American Depositary Shares (“ADSs”) for every 1 ADS held by shareholders, pending shareholder approval and that the dividend is expected to be declared on December 30, 2024, and payable to shareholders who own the Company’s stock at the close of trading on January 2, 2025 (the “Stock Dividend”) . On December 30, 2024, the shareholders of the Company approved the Stock Dividend, and the Company announced that shareholders of record on January 2, 2025 will be entitled to the Stock Dividend, which is expected to be delivered to shareholders on or about January 6, 2025. The Company has been informed that Nasdaq requires that trading in the Company’s ADSs be temporarily halted to allow the orderly distribution of the Stock Dividend. As a result, the Company expects trading of its securities to be halted at the close of trading on January 2, 2025, and to resume at the opening of trading on January 8, 2025 when Nasdaq will process a price change at that time to reflect the underlying dilution. -2- Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TC BIOPHARM (HOLDINGS) PLC By: /s/ Martin Thorp Name: Martin Thorp Title: Chief Financial Officer Date: December 31, 2024 -3-

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing